Early diagnosis is central to meeting the “first 95” goal—ensuring that 95% of people living with HIV know their status. Although global AIDS-related deaths have fallen over the past decades, new infections persist. A key challenge remains the large population unaware of their infection, particularly in areas where access to advanced testing is limited.

Current at-home self-tests primarily detect HIV antibodies, but they typically become positive weeks after exposure—about 25 days in early studies. By contrast, nucleic-acid approaches such as PCR can identify HIV roughly 10 days after infection by measuring viral RNA, yet they require clinic-based workflows, sophisticated instrumentation, and higher cost.

Liu’s strategy targets a different biological signal: the p24 antigen, a protein shed by HIV. Antigen-based tests have historically been considered insufficiently sensitive, often needing closer to 20 days post-infection and typically being run in clinical settings. The project tackles that perceived bottleneck with a new detection mechanism designed for extreme sensitivity without complex preprocessing.

The core innovation combines click chemistry with nanopore sensing, referred to as Click Chemistry Amplified Nanopore (CAN) sensing. The method leverages the ability of target proteins to be detected under conditions that do not demand the intensive sample preparation characteristic of PCR workflows.

In Liu’s earlier validation using real patients, CAN sensing detected p24 in 87.3% of individuals with low viral load, compared with 18.2% detection by ELISA, and reached 100% detection in high viral load cases where ELISA detected 42.1%. The prototype used in that study was about the size of a shoebox.

This NIH-funded phase focuses on transforming proof-of-concept hardware into a self-testing platform. The team will refine the device design and conduct clinical validation with 300 patients in South Carolina through Prisma Health, under the guidance of Helmut Albrecht, medical director of an infectious diseases research center.

Beyond initial screening, the study will also evaluate how the test performs for tracking antigen level changes in patients undergoing antiretroviral therapy. Ultimately, the program targets creation of a spinoff startup to move the technology from lab development to public health impact.

Subject of Research: At-home HIV diagnostics; p24 antigen detection; nanopore sensing; click chemistry
Article Title: At-Home, Lab-Quality HIV Tests Awarded $1.3 Million for Development at UMass Amherst
Web References: https://www.nature.com/articles/s41467-022-34273-x
References: “first test” validation article in Nature Communications (as linked above)
Image Credits: UMass Amherst

The urgency of early HIV detection cannot be overstated. Traditional methods rely on antibody detection, which often takes several weeks post-infection to yield results. Consequently, patients frequently face delays in diagnosis and, concomitantly, treatment. This not only exacerbates the challenges associated with patient care but also significantly hampers efforts in HIV prevention. In stark contrast, the new biosensor leverages the capabilities of microcantilevers coated with specific antibodies that are designed to have a high affinity for HIV antigens. This technology is at the forefront of enhancing sensitivity to detect the virus at much earlier stages of infection, paving the way for timely medical intervention.

One of the remarkable features of this technology is its speed. Instead of waiting for days, this innovative platform can deliver results in minutes, thereby alleviating the anxiety commonly associated with waiting for diagnostic outcomes. The team has demonstrated that this platform could offer testing capabilities comparable to those found in clinical laboratories, but with the added convenience of portability and ease of use. Specifically, the incorporation of a digital readout on the silicon cantilevers transforms complex biochemical interactions into straightforward, easily interpretable data.

The adaptability of this technology is fundamental in addressing the various challenges presented by HIV, particularly the virus’s ability to mutate and form new subtypes. The research team tackled this concern by creating a test that can detect multiple HIV strains, ensuring that it remains effective across different populations worldwide. By functionalizing the test with broadly cross-reactive antibodies, the researchers demonstrated that they could still achieve accurate results even when testing for low concentrations of HIV antigens. This feature is particularly critical, considering the vast genetic diversity of HIV that complicates diagnosis and treatment strategies.

Moreover, the biosensor’s architecture allows it to be manufactured at a low cost without compromising performance. Given the pressing need for efficient testing methods in regions with limited healthcare infrastructure, this advancement is poised to facilitate widespread use. The researchers envision a solar-powered model which could be deployed in hard-to-reach areas, thereby granting vulnerable populations access to critical healthcare resources that were previously unavailable or impractical to obtain.

In addition to HIV, the versatility of this technology opens avenues for diagnosing other infectious diseases. After validation in detecting SARS-CoV-2, the team anticipates expanding its application to target diseases like measles, which has seen a resurgence in various regions. This relevance highlights the technology’s potential impact on broader public health initiatives, particularly in the context of global pandemics where timely interventions are essential to controlling disease transmission.

The collaboration behind this novel technology bridges multiple disciplines, with experts from materials engineering, virology, and micro-nanofabrication contributing their unique knowledge bases. The cross-disciplinary nature of this research showcases the importance of collaborative approaches in tackling complex health challenges and developing effective solutions. Each team member plays a vital role in advancing the project, leveraging their specific expertise to refine the technology and enhance its applicability in real-world settings.

In communicating the significance of their findings, the research team emphasizes the potential for these biosensors to serve as a crucial tool in the broader efforts to manage public health concerns related to HIV and other viral infections. The implications of this work extend beyond mere diagnostics; by enabling faster and more accurate testing, this technology could ultimately reduce transmission rates and improve health outcomes for populations at risk.

As a pioneering approach, this biosensing technology is not merely an incremental improvement but represents an evolution in how healthcare systems can expand their reach, particularly in underserved areas. The necessity for efficient, robust, and cost-effective testing is paramount in the global fight against infectious diseases, making the implications of this research critical for future healthcare strategies.

In conclusion, the advances made by Northwestern University researchers signal a movement towards more equitable healthcare access through innovative testing solutions. With promising developments and tantalizing possibilities for further applications, this research encapsulates the dynamic and forward-thinking nature of contemporary biomedical science, offering hope in the relentless battle against viral infections and associated health disparities.

As this technology continues to develop and undergo further testing, the research community and public health officials alike remain optimistic about its potential to fundamentally change the landscape of disease diagnosis, making strides towards a healthier future for communities around the globe.

Subject of Research: HIV Diagnostic Technology
Article Title: Northwestern Researchers Develop Rapid HIV Testing Technology
News Publication Date: April 2, 2025
Web References: Journal Article
References:
Image Credits:

Keywords

Human immunodeficiency virus, HIV infections, Genetic technology, Virus testing, Antibodies